Hadorta (Dry Extract Of Hederae Folium (Der 4-8:1), Extracting Agent: Ethanol 30 % (M/M))

Hadorta is indicated for the symptomatic relief of cough and mucus retention associated with acute respiratory infections and chronic bronchial conditions. It may be used as part of a broader supportive care plan for respiratory health.

• Relief of productive cough caused by acute upper respiratory tract infections.
• Adjunct therapy for bronchitis to facilitate mucus clearance.
• Supportive treatment for chronic obstructive pulmonary disease (COPD) when a productive cough is present.
• Use in seasonal allergies when cough is a predominant symptom.
• May be combined with non‑pharmacologic measures such as hydration and chest physiotherapy.

Side effects of Hadorta are generally mild and related to its pharmacologic activity on bronchial secretions. Serious adverse events are rare but should be recognized.

Common

• Mild gastrointestinal discomfort or nausea.
• Transient headache.
• Slight increase in salivation.
• Mild skin irritation at the oral mucosa.
• Dizziness, especially when standing quickly.

Serious

• Allergic reactions such as rash, itching, or swelling.
• Severe bronchospasm in sensitive individuals.
• Persistent vomiting or diarrhea.
• Signs of hepatic dysfunction (rare).

Precautions for Hadorta focus on patient selection, underlying conditions, and appropriate use. Patients should follow label instructions and consult healthcare professionals when needed.

• Not recommended for individuals with known hypersensitivity to ivy leaf or ethanol.
• Use caution in patients with asthma or a history of bronchospasm.
• Pregnant or breastfeeding women should seek medical advice before use.
• Avoid prolonged use without medical supervision.
• Keep out of reach of children; accidental ingestion may cause gastrointestinal upset.
• Do not exceed the recommended daily dose.

Hadorta may interact with other medications that affect the respiratory system or liver metabolism. Awareness of potential interactions helps minimize risks.

Avoid

• Concurrent use with other strong expectorants or mucolytics without professional guidance.
• Combination with monoamine oxidase inhibitors (MAOIs) due to possible additive effects on bronchial tone.

Use with caution

• Antihistamines that may cause dry mouth, potentially reducing expectorant effectiveness.
• Hepatically metabolized drugs such as certain statins, as ethanol content could influence metabolism.
• Herbal supplements containing similar expectorant compounds.
• Medications that lower the seizure threshold, though evidence is limited.